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The concurrence of myeloproliferative neoplasms (MPNs) and multiple sclerosis (MS) is unusual. We
report ﬁve patients from a localized geographic area in Denmark with both MS and MPN; all the patients
were diagnosed with MPNs in the years 2007–2012. We describe the patients' history and treatment.
A potential link between MS and MPNs has not been previously recognized. This observation calls
attention to potential environmental factors and/or previously unrecognized genetic factors predisposing
these patients to both MS and MPNs.
& 2013 The Authors. Published by Elsevier Ltd.Open access under CC BY-NC-ND license.1. Introduction
Myeloproliferative neoplasms (MPNs) are stem-cell-derived dis-
orders that cause overproduction of one or more of the formed
elements of the blood. MPNs include chronic myelogenous leuke-
mia (CML) and the Philadelphia-negative MPNs: polycythemia vera
(PV), essential thrombocythemia (ET), primary myeloﬁbrosis (PMF)
and unclassiﬁable MPN (MPN-U) [1]. A gain-of-function mutation in
the gene for Janus kinase 2 (JAK2), the JAK2 V617F mutation, is
found in the majority of patients with PV and about half of patients
with ET and PMF. The etiology of MPNs is unknown, but an
increased risk of MPNs has been found in patients with a family
history of MPNs, prior autoimmune and/or inﬂammatory conditions
and exposure to certain chemicals [2]. Multiple sclerosis (MS) is an
autoimmune inﬂammatory disease of the central nervous system of
unknown etiology. MS can be divided into relapsing-remitting,
primary progressive and secondary progressive MS, depending on
the clinical course [3].
Here we describe four cases of MS-patients that subsequently
developed MPNs and one case of a MPN-patient that developedr Ltd.
skilde Hospital, University of
Tel.: +45 26470824;
Open access under CC BY-NC-NDMS. All ﬁve patients were referred to our centers, in the period of
2007–2012. Two of the patients were diagnosed with PV, the third
with MPN-U, the fourth with ET and the ﬁfth with PMF. All patients
were diagnosed with MS according to the McDonald diagnostic
criteria and with MPNs according to the WHO criteria [1,3].2. Case stories
Case reports with patient characteristics are summarized in
Table 1.3. Discussion
The concurrence of MS and MPN in our series of patients is
unusually high with four patients in the Roskilde MPN-population
alone. The annual incidence rate of MS in Denmark is about 4.44
per 100,000 population, being 37% higher in females than males
[4]. The true incidence of MPNs in Denmark is unknown but is
estimated to be approximately 0.5–1.5 per 100,000 per year for ET
and PV, respectively, and about 0.5 per 100,000 per year for PMF.
Only one case report has previously described the concurrence of a
Philadelphia-negative MPN and MS, which developed during the
course of ET [5]. A potential link between MS and myeloid cancer
has not been previously recognized. A population-based study
from 2010 found no association between previous MS diagnosis
and development of MPNs [6]. For these reasons, the concurrence
of four patients with both MS and MPN in the Roskilde MPN-
population, and an additional patient in another hematological license.
Table 1
Patients characteristics and treatment.
Patient Sex Type of
MPN
Age at MPN
diagnosis
JAK2 V617F
mutation
Blood analysis at
diagnosis
Bone marrow biopsy at diagnosis Type of
MS
Age at MS
diagnosis
MRI MS treatment MPN
treatment
1 F MPN-U 47  Hb 13.4 g/dl Moderately hyperplastic RR 38 Several diffuse areas of increased
T2 signal in the
brain and the cervical spine
Glatiramer
acitate
IFN-alpha
Slight increase in megakaryocytes IFN-beta
Hct 0.43
TLC 16.8109/l Iron status normal
Platelet count
546109/l
RF grade 1
CRP 24 mg/l
LDH 179 U/L
2 F PV 38 + Hb 14.5 g/dl Moderately hyperplastic RR 26 Numerous paraventricular
hyperintense areas,
plaques in the brain stem and in
both cerebral
hemispheres
IFN-beta No
treatmentGlatiramer
acitate
Lively erythropoiesis MitoxantroneHct 0.43
NatalizumabTLC 8.7109/l Normal myelopoiesis
Platelet count
514109/l
Discrete megakaryocytosis
Iron-depleted
RF grade 0
3 M PV 57 + Hb 20.8 g/dl Slightly hyperplastic PP 45 Multiple hyperintense lesions in
the white
substance of the brain
No treatment Hydroxy-
ureaHct 0.60 Slightly increased megakaryocytosis
TLC 12.0109/l Lively erythropoiesis
Platelet count
485109/l
Iron-depleted
4 M ET 46 + Hb 14.8 g/dl Hypercellular RR 46 425 hyperintense lesions in the
white
substance periventricular, in
corpus
callosum, left hemisphere and
pons.
IFN-beta Anagrelide
Lively myelo- and erythropoiesisIncreased
number of megakaryocytes
HCT 0.42
TLC 13.4109/l
Platelet count
829109/l
Low iron status
Plasma EPO
2.8 U/L
5 F PMF 69 + Hb 12.4 g/dl Moderately hyperplastic PP 55 Multiple hyperintense lesions in
the brain stem, cerebellum and
corpus callosum.
No treatment Hydroxy-
ureaLively myelopoiesisHct 0.39
TLC 40.5109/l Increased number of polymorphic
megakaryocytesPlatelet count
992109/l Low iron status
LDH 529 U/l RF grade 3
Plasma EPO o0.1
U/L
EPO, erythropoietin; ET, essential thrombocytosis; Hb, hemoglobin; Hct, hematocrit; JAK2: Janus kinase 2; LDH, lactic acid dehydrogenase; MPN, myeloproliferative neoplasm; MPN-U, myeloproliferative neoplas. m unclassiﬁed;
MS, multiple sclerosis; PMF, primary myeloﬁbrosis; PP, primary progressive; PV, polycythemia vera; TLC, total leukocyte count; RF, Reticulin ﬁbrosis; RR, relapsing-remitting.
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unexpected.
The association between chronic inﬂammation and subsequent
cancer is well established, and chronic inﬂammation is thought to
have a role in both the initiation and promotion of neoplasms [7].
MS is a relapsing inﬂammatory disease of the central nervous
system that leads to damage of nerves and axons. Dysregulation of
the immune system leads to activation of autoreactive lympho-
cytes that migrate across the blood-brain barrier and initiate the
production of pro-inﬂammatory cytokines [8]. Chronic inﬂamma-
tion has been hypothesized to play a role in triggering clonal
evolution in MPNs [7]. Therefore, it is intriguing to consider if
chronic inﬂammation in our ﬁve MS patients may be involved in
the development of their MPNs. In this context it is important to
note that all our patients were relatively newly diagnosed – four
being in the early stage (ET/PV) in the biological continuum, and
one patient diagnosed with myeloﬁbrosis. Many patients with
MPNs have most likely had their cancer for several years before
diagnosis, elevated leukocyte and platelet counts being considered
“reactive”. Accordingly, the inﬂammation drive – having poten-
tially triggered the two illnesses – may have been ongoing for
several years before the clinical diagnosis of MPNs and MS. Other
possibilities to consider in regard to the concurrence of MPNs and
MS are hematological side effects of the MS treatment, environ-
mental or genetic factors.
Finally, it is highly interesting to note that human endogenous
retroviruses have been suggested to play a role in the etiology of
both MS and MPN [7,9]. Supporting this notion, both MS and MPN
are treated with type 1 interferons, which have very potent
antiviral and immunomodulating effects. Indeed, IFN-alpha2 is
able to induce sustained complete hematological remissions with
normalization of the bone marrow even after discontinuation of
interferon-alpha2 for up to three years. Accordingly, endogenous
human retrovirus has most recently been proposed to be involved
in the pathogenesis of MPNs [7].
In conclusion, we report for the ﬁrst time the unusual con-
currence of MS and MPNs in ﬁve patients from a localized
geographic area in Denmark. This observation calls attention to
potential environmental factors and/or previously unrecognized
genetic factors predisposing these patients to both MS and MPN.It also raises the possibility that MPNs might be underdiagnosed in
MS patients, since especially ET and PV patients can have discrete
symptoms. This might contribute to the increased risk of both
venous and arterial thrombosis in MS patients [10]. In the context
that IFN-alpha and -beta interfere with virus replication it is of
interest to consider if chronic inﬂammation – possibly elicited by
virus infection – may trigger and drive MS and MPNs [7]. The
susceptibility to these diseases may be dependent upon the
individual haplotype which may be shared by both diseases.
Further studies are needed to clarify if an association between
MS and MPNs indeed exists in the Danish MS/MPN population or
in distinct areas and – if so – to elucidate common factors which
might explain the concurrence of two rare diseases, including
environmental (e.g. chronic inﬂammation – a role of human
endogenous retrovirus?) or genetic factors (e.g. a common JAK2
haplotype) predisposing the patients to both diseases.References
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